UNSPSC 51321815: Timofibrate

This classification denotes an anti-lipidemic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85P20FW39R. European Medicines Agency schedules Timofibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11068MIG. Timofibrate generally arises in the molecular formula C14H16CLNO4S.

UNSPSC 51321815 Timofibrate is a Commodity code covering prescription pharmaceuticals and related products procured directly by state and local health agencies, emergency services, and cooperative purchasing alliances for clinical use. State and local governments buy specific medication line items under this code for emergency medical services, institutional pharmacy programs, and health benefit initiatives, with vendors typically supplying branded or generic formulations through authorized wholesalers or direct distribution channels. The issuing bodies include city fire and rescue departments, state health and human services commissions, and multi-state cooperative purchasing organizations that aggregate demand across participating jurisdictions. Vendors must comply with FDA requirements, current Good Manufacturing Practices, Drug Supply Chain Security Act certification, and maintain Safety Data Sheets and accessibility documentation as applicable.

Recent activity shows the code active across Florida, Minnesota, and Texas. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem vials for Tampa Fire Rescue, with a response date of April 8, 2026, and an estimated contract value of $40,000, featuring a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct contracting relationships outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract effectiveness July 1, 2026.